Showing results (1-10 of 6) with videos related to
Sort By:
Pageof 1
Expert Opinion on Drug Metabolism & Toxicology|August 14, 2018
Biomarkers of drug-induced acute kidney injury: a regulatory perspectiveMelanie Blank, Aliza Thompson, Elizabeth Hausner, et al.Journal of the American Society of Nephrology : JASN|June 17, 2015
Complete and Partial Remission as Surrogate End Points in Membranous NephropathyAliza Thompson, Daniel C Cattran, Melanie Blank, et al.Acta Biomaterialia|October 20, 2009
Phase composition, mechanical performance and in vitro biocompatibility of hydraulic setting calcium magnesium phosphate cementUwe Klammert, Tobias Reuther, Melanie Blank, et al.Clinical Journal of the American Society of Nephrology : CJASN|March 14, 2020
End Points for Clinical Trials in Primary HyperoxaluriaDawn S Milliner, Tracy L McGregor, Aliza Thompson, et al.Clinical Journal of the American Society of Nephrology : CJASN|June 21, 2023
End Point Considerations for Clinical Trials in Enteric HyperoxaluriaCraig B Langman, Dean Assimos, Melanie Blank, et al.Nature Biotechnology|May 12, 2010
Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing ConsortiumFrank Dieterle, Frank Sistare, Federico Goodsaid, et al.Pageof 1